Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
The Trump-Pharma deals reflect the flaws of state capitalism
Beginning in 2017, President Donald Trump has sought to implement a policy affecting drug prices now known as the “most favored nation” approach, a term borrowed from international trade agreements. The intention is to bar biopharma…
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms. In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to…
Hantavirus cases spark surge in pharma and biotech stocks - here's why
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading. 'With regards to current headlines, we see no meaningful revenue…
Pharma Equity Group's subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant
Pharma Equity Group's subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant Pharma Equity Group A/S today announces that its subsidiary Reponex Pharmaceuticals A/S has received a notification…
$88b bloodbath shows Trump is not the only problem for Aussie pharma giant
There is no longer any pretending that US President Donald Trump and his vaccine sceptic Secretary of Health, Robert F. Kennedy, Jr, are solely to blame for the massive destruction of wealth for investors in Australia's biotechnology champion, CSL.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Eli Lilly (LLY) has shown revenue growth from a position of strength while Pfizer (PFE) is still rebuilding from the COVID cliff. For a retirement-focused investor, one may be more temping now but the other may be the stronger long-term franchise.
Urogen Pharma (NASDAQ:URGN) Now Covered by Analysts at LADENBURG THALM/SH SH
Equities research analysts at LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) in a research note issued on Monday. The brokerage set a 'buy' rating and a $43.00 price target on the stock. LADENBURG…
Hosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRX
Hosking Partners LLP lifted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 91.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned…
27,600 Shares in BridgeBio Pharma, Inc. $BBIO Bought by Swedbank AB
Swedbank AB acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired…
C WorldWide Group Holding A S Has $27.07 Million Stake in Royalty Pharma PLC $RPRX
C WorldWide Group Holding A S lifted its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 700,461 shares of the…
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, HC Wainwright Analyst Says
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price target upped by equities research analysts at HC Wainwright from $100.00 to $110.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a 'buy' rating…
PM austerity appeal unnerves investors
Among the 30 Sensex firms, Titan was the biggest loser, dropping by nearly 7 per cent. InterGlobe Aviation, State Bank of India, Bharti Airtel, Eternal and Reliance Industries were among the major laggards. Sun Pharma, Hindustan Unilever, Adani…
Mitsubishi UFJ Asset Management Co. Ltd. Grows Stock Position in Royalty Pharma PLC $RPRX
Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 15.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission…
3 ways the pros are trading markets right now, including a Goldman strategist on what's next for Kospi
U.S. futures are relatively unchanged as investors monitor U.S.-Iran negotiations. It comes after the S & P 500 hit a record high in Friday trade, posting its sixth positive week in a row for the first time since October 2024. European equities are…
India's M&A market to remain resilient'
Despite an unusually turbulent geopolitical backdrop, India's mergers and acquisitions market is demonstrating remarkable resilience, with deal activity projected to sustain an impressive annual run-rate of approximately $200 billion, driven by…
Receive a Daily briefing on Pharma Industry News
Get Started